ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Sonal Gupta
Matched on ORCID iD 0000-0003-0594-5102; OpenAlex author ID A5004241959. Sources: OpenAlex.
Their work
- Papers
- 10
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 63
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 5 papers · 2020: 1 paper
Papers 10
- Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. Co-author DOI 10.1084/jem.20190354↗
- A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination. Co-author DOI 10.1038/s41374-018-0171-z↗
- Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-1785↗
- Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. Co-author DOI 10.1172/jci.insight.126915↗
- YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.130811↗
- Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Co-author DOI 10.7554/elife.50663↗
- Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism Co-author DOI 10.2139/ssrn.3188491↗
- Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. Co-author DOI 10.1101/gr.222794.117↗
- In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2016.05.063↗
- Molecular determinants of retinoic acid sensitivity in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-11-2165↗
Closest collaborators
The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Anirban Maitra · 10 shared papers, 2012–2020 · strength 0.65
- Paper A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-me… DOI 10.1038/s41374-018-0171-z↗
- Paper Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. DOI 10.1084/jem.20190354↗
- Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
- Ya’an Kang · 4 shared papers, 2016–2019 · strength 0.25
- Paper Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. DOI 10.1172/jci.insight.126915↗
- Paper Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism DOI 10.2139/ssrn.3188491↗
- Paper YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. DOI 10.1172/jci.insight.130811↗
- Jason B. Fleming · 4 shared papers, 2016–2019 · strength 0.25
- Paper Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. DOI 10.1172/jci.insight.126915↗
- Paper Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism DOI 10.2139/ssrn.3188491↗
- Paper YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. DOI 10.1172/jci.insight.130811↗
- Tara N. Fujimoto · 3 shared papers, 2018–2019 · strength 0.22
- Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
- Paper Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. DOI 10.1172/jci.insight.126915↗
- Paper Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism DOI 10.2139/ssrn.3188491↗
- Meifang Yu · 3 shared papers, 2018–2019 · strength 0.22
- Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
- Paper Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. DOI 10.1172/jci.insight.126915↗
- Paper Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism DOI 10.2139/ssrn.3188491↗
- Cullen M. Taniguchi · 3 shared papers, 2018–2019 · strength 0.22
- Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
- Paper Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. DOI 10.1172/jci.insight.126915↗
- Paper Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism DOI 10.2139/ssrn.3188491↗
- Daniel Lin · 3 shared papers, 2018–2019 · strength 0.22
- Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
- Paper Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. DOI 10.1172/jci.insight.126915↗
- Paper Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism DOI 10.2139/ssrn.3188491↗
- Eugene Jon Koay · 3 shared papers, 2018–2019 · strength 0.22
- Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
- Paper Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. DOI 10.1172/jci.insight.126915↗
- Paper Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism DOI 10.2139/ssrn.3188491↗
- Huamin Wang · 3 shared papers, 2016–2020 · strength 0.19
- Paper Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. DOI 10.1084/jem.20190354↗
- Paper YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. DOI 10.1172/jci.insight.130811↗
- Paper In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determin… DOI 10.1016/j.celrep.2016.05.063↗
- Haoqiang Ying · 2 shared papers, 2019 · strength 0.14
- Tushar Damodar Bhagat · 2 shared papers, 2017–2019 · strength 0.12
- Sanchari Bhattacharyya · 2 shared papers, 2017–2019 · strength 0.12
- Amit K. Verma · 2 shared papers, 2017–2019 · strength 0.12
- Timothy Paul Heffernan · 2 shared papers, 2016–2019 · strength 0.11
- Wantong Yao · 2 shared papers, 2016–2019 · strength 0.11
- Giulio Francesco Draetta · 2 shared papers, 2016–2019 · strength 0.11
- Takashi Okumura · 1 shared paper, 2019 · strength 0.09
- Noboru Ideno · 1 shared paper, 2019 · strength 0.09
- Bidyut Ghosh · 1 shared paper, 2019 · strength 0.09
- Michael Goggins · 2 shared papers, 2012–2019 · strength 0.09
- Sulagna Banerjee · 1 shared paper, 2020 · strength 0.08
- Yu Zhang · 1 shared paper, 2020 · strength 0.08
- Erick Marcelo Riquelme Sanchez · 1 shared paper, 2020 · strength 0.08
- Prasanta Dutta · 1 shared paper, 2020 · strength 0.08
- Vidhi Chandra · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.